UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) | August 26, 2014 |
|
Kewaunee Scientific Corporation
(Exact name of registrant as specified in its charter) |
Delaware | 0-5286 | 38-0715562 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
2700 West Front Street Statesville, North Carolina (Address of principal executive offices) |
28677 (Zip Code) |
Registrant’s telephone number, including area code 704-873-7202 |
N/A
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition
On August 26, 2014, Kewaunee Scientific Corporation issued a press release announcing its financial results for the first quarter ended July 31, 2014. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
Exhibit No.
99.1 Press Release of Kewaunee Scientific Corporation dated August 26, 2014
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
(Registrant) | |||
Kewaunee Scientific Corporation | |||
Date: August 26, 2014 | /s/ D. Michael Parker | ||
D. Michael Parker Senior Vice President, Finance | |||
Chief Financial Officer |
Kewaunee Scientific Reports Results for First Quarter
STATESVILLE, N.C., Aug. 26, 2014 /PRNewswire/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported results for its first quarter ended July 31, 2014.
Sales for the quarter were $30,534,000, as compared to sales of $32,003,000 in the first quarter last year. Net earnings for the quarter were $1,234,000, or $0.47 per diluted share, as compared to net earnings of $1,587,000, or $0.61 per diluted share, in the first quarter of the prior year. However, both sales and earnings in the first quarter last year were records for the Company.
Domestic operations sales for the quarter were $24,248,000, a decline of 10% from $27,073,000 in last year's record quarter. The domestic laboratory construction marketplace continued to be challenging during the quarter for projects requiring summer delivery, and pricing remained very competitive. Increased project bidding opportunities were experienced in certain geographic areas of the country, and the Company's number of active outstanding quotations for larger laboratory construction projects is the highest in several years. International operations sales for the quarter were $6,286,000, an increase of 28% over sales of $4,930,000 in the first quarter last year. The Company continues to see good opportunities in the international markets, particularly in the growth markets of India and the Middle East.
The order backlog was $82.7 million at July 31, 2014, as compared to $89.0 million at April 30, 2014 and $71.1 million at July 31, 2013. The Company's backlog is expected to benefit as award decisions are made for the outstanding quotations discussed above.
The Company's balance sheet and financial condition remain strong. Unrestricted cash on hand was $4.4 million at the end of the quarter, unchanged from the end of the first quarter last year. Working capital was $27.5 million, as compared to $24.8 million at the end of the first quarter last year. Borrowings and related interest swaps under the Company's revolving credit facility were $5.2 million at the end of the quarter, as compared to $5.1 million at the end of the first quarter last year, and total bank borrowings and interest rate swaps were $9.7 million, as compared to $10.1 million at the end of the first quarter last year.
"We had a solid quarter, both domestically and internationally," said David M. Rausch, Kewaunee's President and Chief Executive Officer. "Our Associates continue to do an excellent job controlling manufacturing and operating costs, strengthening our relationships with laboratory planners, architects, and customers, winning projects, and strengthening the Kewaunee name globally.
"I am excited about our first facility in China which opened on schedule earlier this month in Suzhou Industrial Park. For some time, we have identified China as one of our key growth markets, and this new facility, combined with an on-going expansion of our sales organization in the country, positions us to build on our business in this large and growing laboratory research market.
"Looking forward, we expect a good second quarter and fiscal year 2015 for sales and earnings. Our expectations are based on our strong order backlog, our projections that the softness in the domestic laboratory marketplace will improve, and anticipated increased opportunities in the international marketplace."
About Kewaunee Scientific
Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Products include steel, wood, and laminate casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin worksurfaces and sinks.
The Company's corporate headquarters are located in Statesville, North Carolina. Direct sales offices are located in the United States, India, Singapore, and China. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company's China headquarters, sales office, and assembly operation are located in Suzhou Industrial Park, China. Kewaunee Scientific's website is located at http://www.kewaunee.com.
This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning these factors is contained in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
| Kewaunee Scientific Corporation | ||||
| Consolidated Statements of Operations (Unaudited) | ||||
| (in thousands, except per share data) | ||||
|
|
|
|
|
|
|
|
| Three months ended | ||
|
|
| July 31, | ||
|
|
| 2014 |
| 2013 |
| Net sales |
| $ 30,534 |
| $ 32,003 |
| Cost of products sold |
| 24,386 |
| 25,427 |
| Gross profit |
| 6,148 |
| 6,576 |
| Operating expenses |
| 4,348 |
| 4,144 |
| Operating earnings |
| 1,800 |
| 2,432 |
| Other income |
| 126 |
| 80 |
| Interest expense |
| (81) |
| (88) |
| Earnings before income taxes |
| 1,845 |
| 2,424 |
| Income tax expense |
| 585 |
| 807 |
| Net earnings |
| 1,260 |
| 1,617 |
| Less: net earnings attributable to the noncontrolling interest |
| 26 |
| 30 |
| Net earnings attributable to Kewaunee Scientific Corporation |
| $ 1,234 |
| $ 1,587 |
|
|
|
|
|
|
| Net earnings per share attributable to |
|
|
|
|
| Kewaunee Scientific Corporation stockholders |
|
|
|
|
| Basic |
| $0.47 |
| $0.61 |
| Diluted |
| $0.47 |
| $0.61 |
|
|
|
|
|
|
| Weighted average number of common shares outstanding |
|
|
|
|
| Basic |
| 2,620 |
| 2,596 |
| Diluted |
| 2,651 |
| 2,618 |
| Kewaunee Scientific Corporation | ||||
| Condensed Consolidated Balance Sheets | ||||
| (in thousands) | ||||
|
|
|
|
|
|
|
|
| July 31, |
| April 30, |
|
|
| 2014 |
| 2014 |
| Assets |
| (Unaudited) |
|
|
| Cash and cash equivalents |
| $ 4,368 |
| $ 6,248 |
| Restricted Cash |
| 2,336 |
| 368 |
| Receivables, less allowances |
| 25,709 |
| 23,473 |
| Inventories |
| 12,213 |
| 11,938 |
| Prepaid expenses and other current assets |
| 2,077 |
| 1,326 |
| Total Current Assets |
| 46,703 |
| 43,353 |
| Net property, plant and equipment |
| 14,483 |
| 14,570 |
| Other assets |
| 4,960 |
| 4,794 |
| Total Assets |
| $ 66,146 |
| $ 62,717 |
|
|
|
|
|
|
| Liabilities and Equity |
|
|
|
|
| Short-term borrowings and interest rate swap |
| $ 5,214 |
| $ 3,150 |
| Current portion of long-term debt |
| 421 |
| 421 |
| Accounts payable |
| 9,131 |
| 8,542 |
| Other current liabilities |
| 4,484 |
| 4,050 |
| Total Current Liabilities |
| 19,250 |
| 16,163 |
| Other non-current liabilities |
| 11,618 |
| 12,330 |
| Total Liabilities |
| 30,868 |
| 28,493 |
| Noncontrolling interest |
| 292 |
| 265 |
| Kewaunee Scientific Corporation equity |
| 34,986 |
| 33,959 |
| Total Equity |
| 35,278 |
| 34,224 |
| Total Liabilities and Equity |
| $ 66,146 |
| $ 62,717 |
Contact: | D. Michael Parker |
| 704/871-3290 |